

Gunderson Dettmer Advises Theravance on Follow-on Public Offering

Client News February 24, 2020

Gunderson Dettmer advised Theravance in a follow-on public offering of 5,500,000 shares at a price to the public of \$27.00 per share for gross proceeds of approximately \$148.5 million. Capital markets partner Jeff Vetter, corporate partner David Young, tax partner Jaime Narayan, and associates Colin Conklin and Tanya Tarczynski led the team advising Theravance.

The joint book-running managers included Morgan Stanley, J.P. Morgan and Cowen.

Theravance, which trades on the Nasdaq under the ticker symbol "TBPH," is a diversified biopharmaceutical company focused on the discovery, development and commercialization of organ-selective medicines.

Related People



Jeffrey R. Vetter PARTNER



David T. Young
MANAGING PARTNER EMERITUS
P +1 650 463 5353



Jaime L. Narayan
PARTNER
P +1 650 463 5374

Related Services

Public Companies

Public Companies/Public Offerings

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California Al Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in "Where the legal battle stands around copyright and AI training"

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding